1-20 of 66
Jeffrey L. Jorgensen, MD PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Comparison of Hyper-CVAD Plus Ofatumumab to Hyper-CVAD Plus Rituximab in Patients with Newly Diagnosed Philadelphia Chromosome-Negative CD20-Positive B-Cell Acute Lymphoblastic Leukemia: A Propensity Score Analysis

Kiyomi Morita, MDPhD, Koji Sasaki, MD, Guillaume Richard-Carpentier, MD, Marina Konopleva, MD PhD, Xuelin Huang, PhD, Nicholas J. Short, MD, Nitin Jain, MD, Farhad Ravandi, MBBS, Bouthaina S. Dabaja, MD, Naval Daver, MD, Tapan M. Kadia, MD, Yesid Alvarado, MD, Courtney D. DiNardo, MD MSCE, Ghayas C. Issa, MD, Naveen Pemmaraju, MD, Guillermo Garcia-Manero, MD, Srdan Verstovsek, MD PhD, Sa A Wang, MD, Joseph D. Khoury, MD, Jeffrey L. Jorgensen, MD PhD, Richard E. Champlin, MD, Issa F. Khouri, MD, Partow Kebriaei, MD, Heather M. Schroeder, Maria Khouri, Koichi Takahashi, MD PhD, Susan M. O'Brien, MD, Hagop M. Kantarjian, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 42–43.
https://doi.org/10.1182/blood-2020-142121
Published: 2020
Journal Articles

Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Trial

Koji Sasaki, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS, Nicholas J. Short, MD, Partow Kebriaei, MD, Xuelin Huang, PhD, Nitin Jain, MD, Marina Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Richard E. Champlin, MD, Tapan M. Kadia, MD, Koichi Takahashi, MD PhD, Naval Daver, MD, Hind Rafei, MD, Joseph D. Khoury, MD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Maria R Khouri, Jovitta Jacob, Rebecca Garris, MSc, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–42.
https://doi.org/10.1182/blood-2020-139896
Published: 2020
Journal Articles

A Prognostic Model for Survival in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia on the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab

Koji Sasaki, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS, Nicholas J. Short, MD, Partow Kebriaei, MD, Xuelin Huang, PhD, Nitin Jain, MD, Marina Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Richard E. Champlin, MD, Tapan M. Kadia, MD, Koichi Takahashi, MD PhD, Hind Rafei, MD, Sa A Wang, MD, Joseph D. Khoury, MD, Jeffrey L. Jorgensen, MD PhD, Maria Khouri, Jovitta Jacob, Rebecca Garris, MSc, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 2–4.
https://doi.org/10.1182/blood-2020-140037
Published: 2020
Journal Articles

Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina) As Salvage Therapy for Patients (Pts) with Acute Lymphoblastic Leukemia (ALL) in First Relapse

Hind Rafei, MD, Hagop M. Kantarjian, MD, Koji Sasaki, MD, Nicholas J. Short, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Joseph D. Khoury, MD, Sa A Wang, MD, Jeffrey L. Jorgensen, MD PhD, Issa F. Khouri, MD, Partow Kebriaei, MD, Nitin Jain, MD, Bouthaina S. Dabaja, MD, Yesid Alvarado, MD, Tapan M. Kadia, MD, Shilpa Paul, PharmD, Serena Chew, PharmD, Guillermo Garcia-Manero, MD, Jan A. Burger, MD PhD, Courtney D. DiNardo, MD MSCE, Naval Daver, MD, Guillermo Montalban-Bravo, MD, Musa Yilmaz, MD, Maro Ohanian, DO, Maria Khouri, Philip A. Thompson, MB, MS, Jovitta Jacob, Meagan Rostykus, RN, Rebecca Garris, MSc, Marina Konopleva, MD PhD, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 36–38.
https://doi.org/10.1182/blood-2020-143386
Published: 2020
Journal Articles

Roleof Allogeneic Stem Cell Transplant (ASCT) in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina): Results from a Phase 2 Study

Hind Rafei, MD, Hagop M. Kantarjian, MD, Koji Sasaki, MD, Nicholas J. Short, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Joseph D. Khoury, MD, Sa A Wang, MD, Jeffrey L. Jorgensen, MD PhD, Issa F. Khouri, MD, Partow Kebriaei, MD, Richard E. Champlin, MD, Nitin Jain, MD, Bouthaina S. Dabaja, MD, Ghayas C. Issa, MD, Naveen Pemmaraju, MD, Tapan M. Kadia, MD, Shilpa Paul, PharmD, Nadya Jammal, PharmD, Guillermo Garcia-Manero, MD, William G. Wierda, MD PhD, Courtney D. DiNardo, MD MSCE, Naval Daver, MD, Guillermo Montalban-Bravo, MD, Rita Khouri, Patrice Nasnas, MD, Philip A. Thompson, MB, MS, Jovitta Jacob, Meagan Rostykus, RN, Rebecca Garris, MSc, Marina Konopleva, MD PhD, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 39–41.
https://doi.org/10.1182/blood-2020-143286
Published: 2020
Journal Articles

Impact of Cytogenetic Abnormalities (CA) on Outcome of Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study

Hind Rafei, MD, Hagop M. Kantarjian, MD, Koji Sasaki, MD, Nicholas J. Short, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Joseph D. Khoury, MD, Sa A Wang, MD, Jeffrey L. Jorgensen, MD PhD, C. Cameron Yin, MD PhD, Issa F. Khouri, MD, Partow Kebriaei, MD, Nitin Jain, MD, Koichi Takahashi, MD PhD, Bouthaina S. Dabaja, MD, Srdan Verstovsek, MD PhD, Tapan M. Kadia, MD, Shilpa Paul, PharmD, Caitlin R. Rausch, PharmD, Guillermo Garcia-Manero, MD, William G. Wierda, MD PhD, Courtney D. DiNardo, MD MSCE, Naval Daver, MD, Guillermo Montalban-Bravo, MD, Musa Yilmaz, MD, Patrice Nasnas, MD, Rita Khouri, Monica Kwari, BSN, Jovitta Jacob, Meagan Rostykus, RN, Rebecca Garris, MSc, Marina Konopleva, MD PhD, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–47.
https://doi.org/10.1182/blood-2020-143401
Published: 2020
Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results

Nitin Jain, MD, Michael J. Keating, MBBS, Philip A. Thompson, MB, MS, Alessandra Ferrajoli, MD, Jan A. Burger, MD PhD, Gautam Borthakur, MD, Koichi Takahashi, MD PhD, Zeev E. Estrov, MD, Koji Sasaki, MD, Nathan H Fowler, MD, Tapan M. Kadia, MD, Marina Konopleva, MD PhD, Yesid Alvarado, MD, Musa Yilmaz, MD, Courtney D. DiNardo, MD MSCE, Prithviraj Bose, MD, Maro Ohanian, DO, Naveen Pemmaraju, MD, Elias Jabbour, MD, Rashmi Kanagal-Shamanna, MD, Keyur Patel, MD PhD, Wei Wang, MD PhD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Naveen Garg, MD, Xuemei Wang, MS, Chongjuan Wei, PhD, Nichole Cruz, RN, Ana Ayala, RN, William Plunkett, PhD, Hagop M. Kantarjian, MD, Varsha Gandhi, PhD, William G. Wierda, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 42–43.
https://doi.org/10.1182/blood-2020-142014
Published: 2020
Journal Articles

Clonal Hematopoiesis and Its Implications for Flow Cytometric Assessment of Measurable Residual Disease in Patients with NPM1- mutated Acute Myeloid Leukemia

Sanam Loghavi, MD, Courtney D. DiNardo, MD MSCE, Koichi Takahashi, MD PhD, Rashmi Kanagal-Shamanna, MD, Tomoyuki Tanaka, MDPhD, Ken Furudate, DDM, PhD, Nicholas J. Short, MD, Tapan M. Kadia, MD, Marina Konopleva, MD PhD, Noushin Farnoud, PhD, Sherry A. Pierce, BSN, BA, Joseph D. Khoury, MD, Jeffrey L. Jorgensen, MD PhD, Keyur P. Patel, MBBS, PhD, L. Jeffrey Medeiros, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS, Sa A Wang, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 38–39.
https://doi.org/10.1182/blood-2020-139871
Published: 2020
Journal Articles

Reduced-Intensity Chemotherapy with Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study

Nicholas J. Short, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Nitin Jain, MD, Tapan M. Kadia, MD, Joseph D. Khoury, MD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Yesid Alvarado, MD, Jan A. Burger, MD PhD, Naval Daver, MD, Gautam Borthakur, MD, Courtney D. DiNardo, MD MSCE, Marina Konopleva, MD PhD, Naveen Pemmaraju, MD, Guillermo Garcia-Manero, MD, William G. Wierda, MD PhD, Steven M. Kornblau, MD, Jovitta Jacob, RN, Meagan Rostykus, RN, Monica Kwari, BSN, Caitlin R. Rausch, PharmD, Christopher Loiselle, BS, Anna Milton, Juan Rivera, Rebecca Garris, MSc, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 15–17.
https://doi.org/10.1182/blood-2020-138569
Published: 2020
Journal Articles

CD22 Expression Level As a Predictor of Survival in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study

Hind Rafei, MD, Hagop M. Kantarjian, MD, Koji Sasaki, MD, Nicholas J. Short, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Joseph D. Khoury, MD, Sa A Wang, MD, Jeffrey L. Jorgensen, MD PhD, Issa F. Khouri, MD, Partow Kebriaei, MD, Nitin Jain, MD, Bouthaina S. Dabaja, MD, Lucia Masarova, MD, Tapan M. Kadia, MD, Shilpa Paul, PharmD, Dan Nichols, Guillermo Garcia-Manero, MD, Jan A. Burger, MD PhD, Courtney D. DiNardo, MD MSCE, Naval Daver, MD, Guillermo Montalban-Bravo, MD, Musa Yilmaz, MD, Prithviraj Bose, MD, Rita Khouri, Philip A. Thompson, MB, MS, Jovitta Jacob, Meagan Rostykus, RN, Rebecca Garris, MSc, Marina Konopleva, MD PhD, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 23–25.
https://doi.org/10.1182/blood-2020-143400
Published: 2020
Journal Articles

Prognostic Value of Measurable Residual Disease after Venetoclax and Decitabine in Acute Myeloid Leukemia

Abhishek Maiti, MBBS, Courtney D. DiNardo, MD MSCE, Sa A Wang, MD, Jeffrey L. Jorgensen, MD PhD, Tapan M. Kadia, MD, Naval Daver, MD, Nicholas J. Short, MD, Musa Yilmaz, MD, Naveen Pemmaraju, MD, Gautam Borthakur, MD, Prithviraj Bose, MD, Ghayas C. Issa, MD, Alessandra Ferrajoli, MD, Elias Jabbour, MD, Nitin Jain, MD, Guillermo Garcia-Manero, MD, Maro Ohanian, DO, Koichi Takahashi, MD PhD, Guillermo Montalban-Bravo, MD, Lucia Masarova, MD, Jan A. Burger, MD PhD, Philip A. Thompson, MB, MS, Srdan Verstovsek, MD PhD, Koji Sasaki, MD, Michael Andreeff, MD PhD, Caitlin R. Rausch, PharmD, Kathryn Montalbano, Sherry A. Pierce, BSN, BA, Hagop M. Kantarjian, MD, Marina Konopleva, MD PhD, Farhad Ravandi, MBBS
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–25.
https://doi.org/10.1182/blood-2020-138773
Published: 2020
Journal Articles

Ultrasensitive Next-Generation Sequencing-Based Measurable Residual Disease Assessment in Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia after Frontline Therapy: Correlation with Flow Cytometry and Impact on Clinical Outcomes

Nicholas J. Short, MD, Hagop M. Kantarjian, MD, Keyur Patel, MD PhD, Steven M. Kornblau, MD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Marina Konopleva, MD PhD, Nitin Jain, MD, Partow Kebriaei, MD, Musa Yilmaz, MD, Ghayas C. Issa, MD, Jairo A. Matthews, Munazza Noor, Rebecca Garris, MSc, Farhad Ravandi, MBBS, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 26–28.
https://doi.org/10.1182/blood-2020-141971
Published: 2020
Journal Articles

Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study

Nicholas J. Short, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Alessandra Ferrajoli, MD, Tapan M. Kadia, MD, Philip A. Thompson, MB, MS, Yesid Alvarado, MD, Nitin Jain, MD, Musa Yilmaz, MD, Joseph D. Khoury, MD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Steven M. Kornblau, MD, Marina Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Heather M Schroeder, Monica Kwari, BSN, Shilpa Paul, PharmD, Benjamin Nwakanme, Christopher Loiselle, BS, Rebecca Garris, MSc, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 9–11.
https://doi.org/10.1182/blood-2020-138565
Published: 2020
Journal Articles

Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD)

Guillaume Richard-Carpentier, MD, Hagop M. Kantarjian, MD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Joseph D. Khoury, MD, Farhad Ravandi, MD, Nicholas J. Short, MD, Rita Khouri, Koichi Takahashi, MD, Maro Ohanian, DO, Gautam M. Borthakur, MD, Marina Y Konopleva, MD PhD, Naval G. Daver, MD, Zeev E. Estrov, MD, Yesid Alvarado, MD, Nitin Jain, MD, Tapan M. Kadia, MD, Guillermo Garcia-Manero, MD, Michelle Velasquez, RN, Patrice Nasnas, MD, Susan O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1299.
https://doi.org/10.1182/blood-2019-130283
Published: 2019
Journal Articles

Achievement of Complete Remission (CR) with Measurable Residual Disease (MRD) Negativity Is Highly Prognostic in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) Receiving First Salvage Chemotherapy

Nicholas J. Short, MD, Hind Rafei, MD, Naval G. Daver, MD, Hyunsoo Hwang, Jing Ning, PhD, Jorge E. Cortes, MD, Jeffrey L. Jorgensen, MD PhD, Tapan M. Kadia, MD, Courtney D. DiNardo, MD MSc, Sa A Wang, MD, Elias Jabbour, MD, Uday Popat, MD, Betul Oran, MDMS, Marina Y Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Gautam M. Borthakur, MD, Kapil N. Bhalla, MD, Ghayas C. Issa, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 735.
https://doi.org/10.1182/blood-2019-122779
Published: 2019
Journal Articles

Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Nicholas J. Short, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Xuelin Huang, PhD, Nitin Jain, MD, Koji Sasaki, MD, Rita Khouri, Naval G. Daver, MD, Naveen Pemmaraju, MD, Joseph D. Khoury, MD, Jeffrey L. Jorgensen, MD PhD, Yesid Alvarado, MD, Marina Y Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, MD, Musa E. Yilmaz, MD, Gautam M. Borthakur, MD, Jan A. Burger, MD PhD, Steven M. Kornblau, MD, William G. Wierda, MD PhD, Courtney D. DiNardo, MD MSc, Alessandra Ferrajoli, MD, Jovitta Jacob, RN, Meagan Rostykus, RN, Rebecca Garris, MSc, Marygrace Ward, RDC, Binru Huang, RDC, Corabelle Encarnacion, RDC, Christopher Loiselle, BS, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 823.
https://doi.org/10.1182/blood-2019-125136
Published: 2019
Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)

Nitin Jain, MD, Michael J Keating, MBBS, Philip A. Thompson, MBBS, Alessandra Ferrajoli, MD, Jan A. Burger, MD PhD, Gautam M. Borthakur, MD, Koichi Takahashi, MD, Zeev E. Estrov, MD, Nathan H. Fowler, MD, Tapan M. Kadia, MD, Marina Y Konopleva, MD PhD, Yesid Alvarado, MD, Musa Yilmaz, MD, Courtney D. DiNardo, MDMSc, Prithviraj Bose, MD, Maro Ohanian, DO, Naveen Pemmaraju, MD, Elias Jabbour, MD, Koji Sasaki, MD, Rashmi Kanagal-Shamanna, MD, Keyur Patel, MD PhD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Naveen Garg, MD, Xuemei Wang, MS, Katrina Sondermann, BA, Nichole Cruz, RN, Chongjuan Wei, PhD, Ana Ayala, RN, William Plunkett, PhD, Hagop M. Kantarjian, MD, Varsha Gandhi, PhD, William G. Wierda, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 34.
https://doi.org/10.1182/blood-2019-131847
Published: 2019
Journal Articles

Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Nicholas J. Short, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Xuelin Huang, PhD, Naval G. Daver, MD, Courtney D. DiNardo, MD MSc, Marina Y Konopleva, MD PhD, Naveen Pemmaraju, MD, William G. Wierda, MD PhD, Guillermo Garcia-Manero, MD, Koji Sasaki, MD, Jorge E. Cortes, MD, Rebecca Garris, MSc, Marygrace Ward, RDC, Binru Huang, RDC, Corabelle Encarnacion, RDC, Christopher Loiselle, BS, Joseph D. Khoury, MD, Jeffrey L. Jorgensen, MD PhD, Nitin Jain, MD, Joie Alvarez, RN, Nicole Tippett, RN, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 283.
https://doi.org/10.1182/blood-2019-125146
Published: 2019
Journal Articles

Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR)

Bachar Samra, MD, Hagop M. Kantarjian, MD, Koji Sasaki, MD, Nicholas J. Short, MD, Rita Khouri, Joseph D. Khoury, MD, Richard E. Champlin, MD, Partow Kebriaei, MD, Jorge E. Cortes, MD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, MD, Gautam M. Borthakur, MD, Srdan Verstovsek, MD PhD, Naval G. Daver, MD, Guillermo Montalban-Bravo, MD, Nitin Jain, MD, Marina Y Konopleva, MD PhD, Musa E. Yilmaz, MD, Kiran Naqvi, MDMPH, Susan M. O'Brien, MD, Farhad Ravandi, MD, Elias Jabbour, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 287.
https://doi.org/10.1182/blood-2019-127516
Published: 2019
Journal Articles

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV -Mutated CLL and without Del(17p)/Mutated TP53

Nitin Jain, MD, Philip A. Thompson, MBBS, Jan A. Burger, MD PhD, Alessandra Ferrajoli, MD, Koichi Takahashi, MD, Zeev E. Estrov, MD, Gautam M. Borthakur, MD, Prithviraj Bose, MD, Tapan M. Kadia, MD, Naveen Pemmaraju, MD, Koji Sasaki, MD, Naveen Garg, MD, Xuemei Wang, MS, Rashmi Kanagal-Shamanna, MD, Keyur Patel, MD PhD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Wanda Lopez, RN, Ana Ayala, RN, William Plunkett, PhD, Varsha Gandhi, PhD, Hagop M. Kantarjian, MD, Susan O'Brien, MD, Michael J Keating, MBBS, William G. Wierda, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 357.
https://doi.org/10.1182/blood-2019-131939
Published: 2019